Zentalis Pharmaceuticals (NASDAQ: ZNTL) is a clinical‐stage oncology company dedicated to the discovery and development of small molecule therapeutics designed to target key drivers of cancer growth and resistance. Since its founding in 2017, the company has built a robust pipeline grounded in precision science, with a focus on cell cycle and DNA damage response pathways. By leveraging proprietary chemistry technologies and structure-based drug design, Zentalis aims to deliver novel candidates that address unmet needs in solid tumors and hematologic malignancies.
The company’s lead asset, ZN‐C3, is a potent and selective WEE1 kinase inhibitor in Phase 2 development for patients with platinum‐resistant ovarian and other advanced solid tumors. ZN‐D5, a highly selective PLK1 inhibitor, is being evaluated for safety and efficacy both as a monotherapy and in combination with established chemotherapies. In addition to these clinical programs, Zentalis has a preclinical portfolio that includes inhibitors of ATR, CHK1, and other DNA damage repair targets, with the goal of creating rational combination regimens to enhance anti‐tumor activity and overcome resistance mechanisms.
Headquartered in New York City, Zentalis maintains research facilities in both the United States and Europe to support its global development strategy. The company collaborates with leading academic institutions and cancer centers to conduct early-stage trials and accelerate patient access to investigational therapies. Zentalis has also entered strategic partnerships with pharmaceutical companies to expand clinical development, access novel technologies, and prepare for potential commercialization of its most advanced programs.
Zentalis is led by a management team with extensive experience in oncology drug development, manufacturing, and regulatory affairs. Its executive leadership includes members who have played key roles in bringing multiple oncology products from discovery through approval. The company’s board of directors and scientific advisory board comprise seasoned experts in cancer biology, translational research, and clinical strategy, underscoring Zentalis’s commitment to advancing innovative therapies for patients with high‐unmet‐need cancers.
AI Generated. May Contain Errors.
